We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

321 hedge funds and large institutions have $8.94B invested in BioMarin Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 128 increasing their positions, 103 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more call options, than puts

Call options by funds: $140M | Put options by funds: $100M

38% more funds holding in top 10

Funds holding in top 10: 8 → 11 (+3)

25% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 36

24% more repeat investments, than reductions

Existing positions increased: 128 | Existing positions reduced: 103

3% more funds holding

Funds holding: 313 → 321 (+8)

14% less capital invested

Capital invested by funds: $10.4B → $8.94B (-$1.45B)

Holders
321
Holders Change
+8
Holders Change %
+2.56%
% of All Funds
9.23%
Holding in Top 10
11
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+37.5%
% of All Funds
0.32%
New
45
Increased
128
Reduced
103
Closed
36
Calls
$140M
Puts
$100M
Net Calls
+$40.2M
Net Calls Change
+$53.1M

Top Buyers

1
Sands Capital Management
Sands Capital Management
Virginia
+$132M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$116M
3
Millennium Management
Millennium Management
New York
+$82M
4
Norges Bank
Norges Bank
Norway
+$67.5M
5
WRF
Waddell & Reed Financial
Kansas
+$35.7M

Top Sellers

1
Winslow Capital Management
Winslow Capital Management
Minnesota
-$291M
2
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$177M
3
Jennison Associates
Jennison Associates
New York
-$161M
4
Capital World Investors
Capital World Investors
California
-$76.4M
5
HCM
Holland Capital Management
Illinois
-$53.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Capital Research Global Investors
1
Capital Research Global Investors
California
$1.11B +$5.95M +98,420 +0.6%
Sands Capital Management
2
Sands Capital Management
Virginia
$742M +$132M +2,187,583 +22%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$573M +$116M +1,919,366 +26%
Vanguard Group
4
Vanguard Group
Pennsylvania
$512M +$11.8M +195,583 +2%
Primecap Management
5
Primecap Management
California
$502M -$6.01M -99,500 -1%
Jennison Associates
6
Jennison Associates
New York
$333M -$161M -2,672,017 -33%
State Street
7
State Street
Massachusetts
$269M +$25.8M +426,323 +11%
BIT
8
BlackRock Institutional Trust
California
$219M +$2.82M +46,597 +1%
Wells Fargo
9
Wells Fargo
California
$182M -$33.1M -547,340 -16%
BFA
10
BlackRock Fund Advisors
California
$176M -$590K -9,771 -0.3%
Norges Bank
11
Norges Bank
Norway
$139M +$67.5M +1,116,833 +100%
William Blair & Company
12
William Blair & Company
Illinois
$137M -$12.7M -210,442 -9%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$134M -$8.85M -146,424 -6%
TG
14
TCW Group
California
$134M -$12.8M -212,597 -9%
AC
15
Amici Capital
New York
$133M +$19.8M +328,440 +18%
Temasek Holdings
16
Temasek Holdings
Singapore
$133M +$35.1M +580,924 +37%
BBA
17
Baker Bros. Advisors
New York
$119M +$1.51M +25,000 +1%
AGA
18
Altrinsic Global Advisors
Connecticut
$114M +$327K +5,408 +0.3%
Franklin Resources
19
Franklin Resources
California
$114M +$6.71M +111,000 +6%
WRF
20
Waddell & Reed Financial
Kansas
$99.3M +$35.7M +590,149 +59%
MCM
21
Munder Capital Management
Michigan
$95.7M -$4.35M -72,013 -4%
Alkeon Capital Management
22
Alkeon Capital Management
New York
$95.4M +$4.91M +81,275 +6%
O
23
OrbiMed
New York
$89.3M -$3.48M -57,600 -4%
Millennium Management
24
Millennium Management
New York
$86.4M +$82M +1,356,725 +4,199%
Neuberger Berman Group
25
Neuberger Berman Group
New York
$77.2M -$26.4M -436,696 -26%
1
2 3 4 5

BMRN Hedge Fund Activity: Q2 2014 in Review

321 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2014, worth a combined $8.94B — down 14% from $10.4B a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new BMRN positions and 36 closed out — a net gain of 9 holders — while 128 added to existing stakes and 103 trimmed.

The largest buyer was Sands Capital Management, adding an estimated $132M. The largest seller was Winslow Capital Management, cutting an estimated $291M.

  • 321 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2014, up from 313 in Q1 2014.
  • Funds reported $8.94B of BioMarin Pharmaceuticals stock for Q2 2014, down 14% quarter-over-quarter.
  • 45 funds opened new BioMarin Pharmaceuticals positions in Q2 2014 and 36 closed out, a net change of +9 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q2 2014 was Sands Capital Management, an estimated $132M added.
  • The largest BioMarin Pharmaceuticals seller in Q2 2014 was Winslow Capital Management, an estimated $291M sold.

Based on aggregated 13F filings for Q2 2014.